An extended antibody microarray for surface profiling metastatic melanoma

Journal of Immunological Methods

Volumn 358, Issue 1-2, 2010, Pages 23-34

  Kaufman, Kimberley L ^a   Belov, Larissa ^a   Huang, Pauline ^a   Mactier, Swetlana ^a   Scolyer, Richard A ^b,c,d   Mann, Graham J ^a,c   Christopherson, Richard I ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c MELANOMA INSTITUTE AUSTRALIA   (Australia)

^d University of Sydney   (Australia)

Author keywords

Antibody microarray; Metastatic melanoma; Prognosis; Surface antigen

Indexed keywords

ANTIBODY; ANTIGEN; CD45 ANTIGEN; PYROXYLIN;

ADULT; AGED; ANTIBODY DETECTION; ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; CANCER GROWTH; CANCER TISSUE; CELL SUSPENSION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOASSAY; IMMUNOPHENOTYPING; LEUKOCYTE; LYMPH NODE METASTASIS; MALE; MELANOCYTE; MELANOMA; MELANOMA CELL; MICROARRAY ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN IMMOBILIZATION; PROTEOMICS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES; ANTIGENS, CD; ANTIGENS, SURFACE; CELL LINE, TUMOR; FEMALE; HUMANS; LYMPH NODES; MALE; MELANOCYTES; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; PROTEIN ARRAY ANALYSIS; TUMOR CELLS, CULTURED;

EID: 77953290713     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2010.03.017     Document Type: Article

References (79)

1. Ahmed N.U., Ueda M., Ito A., Ohashi A., Funasaka Y., Ichihashi M. Expression of fibroblast growth factor receptors in naevus-cell naevus and malignant melanoma. Melanoma Res. 1997, 7:299-305.
2. Altomonte M., Gloghini A., Bertola G., Gasparollo A., Carbone A., Ferrone S., Maio M. Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells. Cancer Res. 1993, 53:3343-3348.
3. Bachmann I.M., Straume O., Puntervoll H.E., Kalvenes M.B., Akslen L.A. Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. Clin. Cancer Res. 2005, 11:8606-8614.
4. Balch C.M., Soong S.J., Gershenwald J.E., Thompson J.F., Reintgen D.S., Cascinelli N., Urist M., McMasters K.M., Ross M.I., Kirkwood J.M., Atkins M.B., Thompson J.A., Coit D.G., Byrd D., Desmond R., Zhang Y., Liu P.Y., Lyman G.H., Morabito A. Prognostic factors analysis of 17, 600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J. Clin. Oncol. 2001, 19:3622-3634.
5. Barber N., Belov L., Christopherson R.I. All-trans retinoic acid induces different immunophenotypic changes on human HL60 and NB4 myeloid leukaemias. Leuk. Res. 2008, 32:315-322.
6. Baruch A.C., Shi J., Feng Y., Nelson M.A. New developments in the staging of melanoma. Cancer Invest. 2005, 23:561-567.
7. Belov L., de la Vega O., dos Remedios C.G., Mulligan S.P., Christopherson R.I. Immunophenotyping of leukemias using a cluster of differentiation antibody microarray. Cancer Res. 2001, 61:4483-4489.
8. Belov L., Huang P., Barber N., Mulligan S.P., Christopherson R.I. Identification of repertoires of surface antigens on leukemias using an antibody microarray. Proteomics 2003, 3:2147-2154.
9. Belov L., Mulligan S.P., Barber N., Woolfson A., Scott M., Stoner K., Chrisp J.S., Sewell W.A., Bradstock K.F., Bendall L., Pascovici D.S., Thomas M., Erber W., Huang P., Sartor M., Young G.A., Wiley J.S., Juneja S., Wierda W.G., Green A.R., Keating M.J., Christopherson R.I. Analysis of human leukaemias and lymphomas using extensive immunophenotypes from an antibody microarray. Br. J. Haematol. 2006, 135:184-197.
10. Bilalovic N., Sandstad B., Golouh R., Nesland J.M., Selak I., Torlakovic E.E. CD10 protein expression in tumor and stromal cells of malignant melanoma is associated with tumor progression. Mod. Pathol. 2004, 17:1251-1258.
11. Bron L.P., Scolyer R.A., Thompson J.F., Hersey P. Histological expression of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in human primary melanoma. Pathology 2004, 36:561-565.
12. Casado J.G., Delgado E., Patsavoudi E., Duran E., Sanchez-Correa B., Morgado S., Solana R., Tarazona R. Functional implications of HNK-1 expression on invasive behaviour of melanoma cells. Tumour Biol. 2008, 29:304-310.
13. Cruz J., Reis-Filho J.S., Silva P., Lopes J.M. Expression of c-met tyrosine kinase receptor is biologically and prognostically relevant for primary cutaneous malignant melanomas. Oncology 2003, 65:72-82.
14. Curtin J.A., Busam K., Pinkel D., Bastian B.C. Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol. 2006, 24:4340-4346.
15. Danen E.H., Ten Berge P.J., Van Muijen G.N., Van't Hof-Grootenboer A.E., Brocker E.B., Ruiter D.J. Emergence of alpha 5 beta 1 fibronectin- and alpha v beta 3 vitronectin-receptor expression in melanocytic tumour progression. Histopathology 1994, 24:249-256.
16. Dietrich A., Tanczos E., Vanscheidt W., Schopf E., Simon J.C. High CD44 surface expression on primary tumours of malignant melanoma correlates with increased metastatic risk and reduced survival. Eur. J. Cancer 1997, 33:926-930.
17. Dzhandzhugazyan K.N., Kirkin A.F., thor Straten P., Zeuthen J. Ecto-ATP diphosphohydrolase/CD39 is overexpressed in differentiated human melanomas. FEBS Lett. 1998, 430:227-230.
18. Ellmark P., Belov L., Huang P., Lee C.S., Solomon M.J., Morgan D.K., Christopherson R.I. Multiplex detection of surface molecules on colorectal cancers. Proteomics 2006, 6:1791-1802.
19. Fogel M., Mechtersheimer S., Huszar M., Smirnov A., Abu-Dahi A., Tilgen W., Reichrath J., Georg T., Altevogt P., Gutwein P. L1 adhesion molecule (CD 171) in development and progression of human malignant melanoma. Cancer Lett. 2003, 189:237-247.
20. Fujii H., Nakajima M., Saiki I., Yoneda J., Azuma I., Tsuruo T. Human melanoma invasion and metastasis enhancement by high expression of aminopeptidase N/CD13. Clin. Exp. Metastasis 1995, 13:337-344.
21. Giehl K.A., Nagele U., Volkenandt M., Berking C. Protein expression of melanocyte growth factors (bFGF, SCF) and their receptors (FGFR-1, c-kit) in nevi and melanoma. J. Cutan Pathol. 2007, 34:7-14.
22. Hess A.R., Seftor E.A., Gruman L.M., Kinch M.S., Seftor R.E., Hendrix M.J. VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications for vasculogenic mimicry. Cancer Biol. Ther. 2006, 5:228-233.
23. Hong I.K., Kim Y.M., Jeoung D.I., Kim K.C., Lee H. Tetraspanin CD9 induces MMP-2 expression by activating p38 MAPK, JNK and c-Jun pathways in human melanoma cells. Exp. Mol. Med. 2005, 37:230-239.
24. Hotta H., Ross A.H., Huebner K., Isobe M., Wendeborn S., Chao M.V., Ricciardi R.P., Tsujimoto Y., Croce C.M., Koprowski H. Molecular cloning and characterization of an antigen associated with early stages of melanoma tumor progression. Cancer Res. 1988, 48:2955-2962.
25. Huttenbach Y., Prieto V.G., Reed J.A. Desmoplastic and spindle cell melanomas express protein markers of the neural crest but not of later committed stages of Schwann cell differentiation. J. Cutan Pathol. 2002, 29:562-568.
26. Ilmonen S., Vaheri A., Asko-Seljavaara S., Carpen O. Ezrin in primary cutaneous melanoma. Mod. Pathol. 2005, 18:503-510.
27. Johnson J.P. Cell adhesion molecules in the development and progression of malignant melanoma. Cancer Metastasis Rev. 1999, 18:345-357.
28. Jones D.H., Nakashima T., Sanchez O.H., Kozieradzki I., Komarova S.V., Sarosi I., Morony S., Rubin E., Sarao R., Hojilla C.V., Komnenovic V., Kong Y.Y., Schreiber M., Dixon S.J., Sims S.M., Khokha R., Wada T., Penninger J.M. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006, 440:692-696.
29. Kanekura T., Chen X., Kanzaki T. Basigin (CD147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts. Int. J. Cancer 2002, 99:520-528.
30. Kanitakis J., Narvaez D., Claudy A. Differential expression of the CD10 antigen (neutral endopeptidase) in primary versus metastatic malignant melanomas of the skin. Melanoma Res. 2002, 12:241-244.
31. Karjalainen J.M., Tammi R.H., Tammi M.I., Eskelinen M.J., Agren U.M., Parkkinen J.J., Alhava E.M., Kosma V.M. Reduced level of CD44 and hyaluronan associated with unfavorable prognosis in clinical stage I cutaneous melanoma. Am. J. Pathol. 2000, 157:957-965.
32. Kim K.B., Eton O., Davis D.W., Frazier M.L., McConkey D.J., Diwan A.H., Papadopoulos N.E., Bedikian A.Y., Camacho L.H., Ross M.I., Cormier J.N., Gershenwald J.E., Lee J.E., Mansfield P.F., Billings L.A., Ng C.S., Charnsangavej C., Bar-Eli M., Johnson M.M., Murgo A.J., Prieto V.G. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br. J. Cancer 2008, 99:734-740.
33. Kirkin A.F., Dzhandzhugazyan K., Zeuthen J. Melanoma-associated antigens recognized by cytotoxic T lymphocytes. Apmis 1998, 106:665-679.
34. Klein W.M., Wu B.P., Zhao S., Wu H., Klein-Szanto A.J., Tahan S.R. Increased expression of stem cell markers in malignant melanoma. Mod. Pathol. 2007, 20:102-107.
35. Kreizenbeck G.M., Berger A.J., Subtil A., Rimm D.L., Gould Rothberg B.E. Prognostic significance of cadherin-based adhesion molecules in cutaneous malignant melanoma. Cancer Epidemiol. Biomarkers Prev. 2008, 17:949-958.
36. Kuzbicki L., Gajo B., Chwirot B.W. Different expression of lysosome-associated membrane protein-1 in human melanomas and benign melanocytic lesions. Melanoma Res. 2006, 16:235-243.
37. Kwon B.S., Chintamaneni C., Kozak C.A., Copeland N.G., Gilbert D.J., Jenkins N., Barton D., Francke U., Kobayashi Y., Kim K.K. A melanocyte-specific gene, Pmel 17, maps near the silver coat color locus on mouse chromosome 10 and is in a syntenic region on human chromosome 12. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:9228-9232.
38. Lal S., Lui R., Nguyen L., Macdonald P., Denyer G., dos Remedios C. Increases in leukocyte cluster of differentiation antigen expression during cardiopulmonary bypass in patients undergoing heart transplantation. Proteomics 2004, 4:1918-1926.
39. Lehmann J.M., Riethmuller G., Johnson J.P. MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:9891-9895.
40. Leotlela P.D., Wade M.S., Duray P.H., Rhode M.J., Brown H.F., Rosenthal D.T., Dissanayake S.K., Earley R., Indig F.E., Nickoloff B.J., Taub D.D., Kallioniemi O.P., Meltzer P., Morin P.J., Weeraratna A.T. Claudin-1 overexpression in melanoma is regulated by PKC and contributes to melanoma cell motility. Oncogene 2007, 26:3846-3856.
41. Liu, B., Ma, J., Wang, X., Su, F., Li, X., Yang, S., Ma, W., Zhang, Y., 2008. Lymphangiogenesis and Its Relationship With Lymphatic Metastasis and Prognosis in Malignant Melanoma. Anat Rec (Hoboken).
42. Marchetti D., Denkins Y., Reiland J., Greiter-Wilke A., Galjour J., Murry B., Blust J., Roy M. Brain-metastatic melanoma: a neurotrophic perspective. Pathol. Oncol. Res. 2003, 9:147-158.
43. McGary E.C., Lev D.C., Bar-Eli M. Cellular adhesion pathways and metastatic potential of human melanoma. Cancer Biol. Ther. 2002, 1:459-465.
44. Meier F., Busch S., Gast D., Goppert A., Altevogt P., Maczey E., Riedle S., Garbe C., Schittek B. The adhesion molecule L1 (CD171) promotes melanoma progression. Int. J. Cancer 2006, 119:549-555.
45. Monteagudo C., Martin J.M., Jorda E., Llombart-Bosch A. CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors. J. Clin. Pathol. 2007, 60:596-599.
46. Nikkola J., Vihinen P., Vlaykova T., Hahka-Kemppinen M., Heino J., Pyrhonen S. Integrin chains beta1 and alphav as prognostic factors in human metastatic melanoma. Melanoma Res. 2004, 14:29-37.
47. Owen-Schaub L.B., van Golen K.L., Hill L.L., Price J.E. Fas and Fas ligand interactions suppress melanoma lung metastasis. J. Exp. Med. 1998, 188:1717-1723.
48. Petermann K.B., Rozenberg G.I., Zedek D., Groben P., McKinnon K., Buehler C., Kim W.Y., Shields J.M., Penland S., Bear J.E., Thomas N.E., Serody J.S., Sharpless N.E. CD200 is induced by ERK and is a potential therapeutic target in melanoma. J. Clin. Invest. 2007, 117:3922-3929.
49. Puri N., Ahmed S., Janamanchi V., Tretiakova M., Zumba O., Krausz T., Jagadeeswaran R., Salgia R. c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin. Cancer Res. 2007, 13:2246-2253.
50. Ravindranath N.M., Shuler C. Cell-surface density of complement restriction factors (CD46, CD55, and CD59): oral squamous cell carcinoma versus other solid tumors. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2007, 103:231-239.
51. Reschke M., Mihic-Probst D., van der Horst E.H., Knyazev P., Wild P.J., Hutterer M., Meyer S., Dummer R., Moch H., Ullrich A. HER3 is a determinant for poor prognosis in melanoma. Clin. Cancer Res. 2008, 14:5188-5197.
52. Rolland Y., Demeule M., Fenart L., Beliveau R. Inhibition of melanoma brain metastasis by targeting melanotransferrin at the cell surface. Pigment Cell Melanoma Res. 2009, 22:86-98.
53. Saalbach A., Wetzel A., Haustein U.F., Sticherling M., Simon J.C., Anderegg U. Interaction of human Thy-1 (CD 90) with the integrin alphavbeta3 (CD51/CD61): an important mechanism mediating melanoma cell adhesion to activated endothelium. Oncogene 2005, 24:4710-4720.
54. Sadej R., Spychala J., Skladanowski A.C. Ecto-5'-nucleotidase (eN, CD73) is coexpressed with metastasis promoting antigens in human melanoma cells. Nucleosides Nucleotides Nucleic Acids 2006, 25:1119-1123.
55. Sadej R., Spychala J., Skladanowski A.C. Expression of ecto-5'-nucleotidase (eN, CD73) in cell lines from various stages of human melanoma. Melanoma Res. 2006, 16:213-222.
56. Scala S., Ottaiano A., Ascierto P.A., Cavalli M., Simeone E., Giuliano P., Napolitano M., Franco R., Botti G., Castello G. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin. Cancer Res. 2005, 11:1835-1841.
57. Sekulic A., Haluska P., Miller A.J., Genebriera De Lamo J., Ejadi S., Pulido J.S., Salomao D.R., Thorland E.C., Vile R.G., Swanson D.L., Pockaj B.A., Laman S.D., Pittelkow M.R., Markovic S.N. Malignant melanoma in the 21st century: the emerging molecular landscape. Mayo Clin. Proc. 2008, 83:825-846.
58. Si Z., Hersey P. Expression of the neuroglandular antigen and analogues in melanoma. CD9 expression appears inversely related to metastatic potential of melanoma. Int. J. Cancer 1993, 54:37-43.
59. Smalley K.S., Nathanson K.L., Flaherty K.T. Genetic subgrouping of melanoma reveals new opportunities for targeted therapy. Cancer Res. 2009, 69:3241-3244.
60. Streit S., Mestel D.S., Schmidt M., Ullrich A., Berking C. FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients. Br. J. Cancer 2006, 94:1879-1886.
61. Swart G.W., Lunter P.C., Kilsdonk J.W., Kempen L.C. Activated leukocyte cell adhesion molecule (ALCAM/CD166): signaling at the divide of melanoma cell clustering and cell migration?. Cancer Metastasis Rev. 2005, 24:223-236.
62. Tellez C.S., Davis D.W., Prieto V.G., Gershenwald J.E., Johnson M.M., McCarty M.F., Bar-Eli M. Quantitative analysis of melanocytic tissue array reveals inverse correlation between activator protein-2alpha and protease-activated receptor-1 expression during melanoma progression. J. Invest. Dermatol. 2007, 127:387-393.
63. Thies A., Moll I., Berger J., Wagener C., Brummer J., Schulze H.J., Brunner G., Schumacher U. CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. J. Clin. Oncol. 2002, 20:2530-2536.
64. Thies A., Schachner M., Moll I., Berger J., Schulze H.J., Brunner G., Schumacher U. Overexpression of the cell adhesion molecule L1 is associated with metastasis in cutaneous malignant melanoma. Eur. J. Cancer 2002, 38:1708-1716.
65. Thies A., Schachner M., Berger J., Moll I., Schulze H.J., Brunner G., Schumacher U. The developmentally regulated neural crest-associated glycotope HNK-1 predicts metastasis in cutaneous malignant melanoma. J. Pathol. 2004, 203:933-939.
66. Thompson J.F., Scolyer R.A., Kefford R.F. Cutaneous melanoma. Lancet 2005, 365:687-701.
67. Thompson J.F., Scolyer R.A., Kefford R.F. Cutaneous melanoma in the era of molecular profiling. Lancet 2009, 374:362-365.
68. Thorne R.F., Marshall J.F., Shafren D.R., Gibson P.G., Hart I.R., Burns G.F. The integrins alpha3beta1 and alpha6beta1 physically and functionally associate with CD36 in human melanoma cells. Requirement for the extracellular domain OF CD36. J. Biol. Chem. 2000, 275:35264-35275.
69. Timar J., Raso E., Dome B., Ladanyi A., Banfalvi T., Gilde K., Raz A. Expression and function of the AMF receptor by human melanoma in experimental and clinical systems. Clin. Exp. Metastasis 2002, 19:225-232.
70. Trabado S., Nguyen Van Binh P., Martin C., Lafarge-Frayssinet C., Thevenin M., Baudouin F., Warnet J.M., Duc H.T. Modulated expression of cell surface molecules and in vivo outgrowth of modified melanoma cells. Biomed. Pharmacother. 2006, 60:693-697.
71. Tse K.F., Jeffers M., Pollack V.A., McCabe D.A., Shadish M.L., Khramtsov N.V., Hackett C.S., Shenoy S.G., Kuang B., Boldog F.L., MacDougall J.R., Rastelli L., Herrmann J., Gallo M., Gazit-Bornstein G., Senter P.D., Meyer D.L., Lichenstein H.S., LaRochelle W.J. CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. Clin. Cancer Res. 2006, 12:1373-1382.
72. Tsutsumi S., Neckers L. Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis. Cancer Sci. 2007, 98:1536-1539.
73. van den Oord J.J., Maes A., Stas M., Nuyts J., Battocchio S., Kasran A., Garmyn M., De Wever I., De Wolf-Peeters C. CD40 is a prognostic marker in primary cutaneous malignant melanoma. Am. J. Pathol. 1996, 149:1953-1961.
74. van Kempen L.C., Meier F., Egeblad M., Kersten-Niessen M.J., Garbe C., Weidle U.H., Van Muijen G.N., Herlyn M., Bloemers H.P., Swart G.W. Truncation of activated leukocyte cell adhesion molecule: a gateway to melanoma metastasis. J. Invest. Dermatol. 2004, 122:1293-1301.
75. Varney M.L., Li A., Dave B.J., Bucana C.D., Johansson S.L., Singh R.K. Expression of CXCR1 and CXCR2 receptors in malignant melanoma with different metastatic potential and their role in interleukin-8 (CXCL-8)-mediated modulation of metastatic phenotype. Clin. Exp. Metastasis 2003, 20:723-731.
76. White S.L., Belov L., Barber N., Hodgkin P.D., Christopherson R.I. Immunophenotypic changes induced on human HL60 leukaemia cells by 1alpha, 25-dihydroxyvitamin D3 and 12-O-tetradecanoyl phorbol-13-acetate. Leuk. Res. 2005, 29:1141-1151.
77. Woolfson A., Stebbing J., Tom B.D., Stoner K.J., Gilks W.R., Kreil D.P., Mulligan S.P., Belov L., Chrisp J.S., Errington W., Wildfire A., Erber W.N., Bower M., Gazzard B., Christopherson R.I., Scott M.A. Conservation of unique cell-surface CD antigen mosaics in HIV-1-infected individuals. Blood 2005, 106:1003-1007.
78. Wu J.Q., Wang B., Belov L., Chrisp J., Learmont J., Dyer W.B., Zaunders J., Cunningham A.L., Dwyer D.E., Saksena N.K. Antibody microarray analysis of cell surface antigens on CD4+ and CD8+ T cells from HIV+ individuals correlates with disease stages. Retrovirology 2007, 4:83.
79. Zhou J., Belov L., Huang P.Y., Shin J.S., Solomon M.J., Chapuis P.H., Bokey L., Chan C., Clarke C., Clarke S.J., Christopherson R.I. Surface antigen profiling of colorectal cancer using antibody microarrays with fluorescence multiplexing. J. Immunol. Methods 2010, 355:40-51.